Trending...
- CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
- Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
- Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 13, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) securities between May 11, 2020 and November 4, 2020, inclusive (the "Class Period").
Investors suffering losses on their bluebird investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for LentiGlobin for sickle cell disease in the second half of 2021.
On November 4, 2020, post-market, bluebird disclosed that it would delay its BLA submission to late 2022 due to "feedback" from the FDA that requires the Company to provide additional data "to demonstrate drug product comparability" for LentiGlobin for sickle cell disease, as well as "COVID-19 related shifts and contract manufacturing organization COVID-19 impacts."
More on The PennZone
On this news, bluebird's stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (2) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
If you purchased or otherwise acquired bluebird securities during the Class Period, you may move the Court no later than April 13, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Investors suffering losses on their bluebird investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for LentiGlobin for sickle cell disease in the second half of 2021.
On November 4, 2020, post-market, bluebird disclosed that it would delay its BLA submission to late 2022 due to "feedback" from the FDA that requires the Company to provide additional data "to demonstrate drug product comparability" for LentiGlobin for sickle cell disease, as well as "COVID-19 related shifts and contract manufacturing organization COVID-19 impacts."
More on The PennZone
- Philadelphia Community Invited to Unite for Praise-A-Thon Summer Concert Benefiting Cobbs Creek
- Lineus Medical Signs Partnership Agreement with DIMA MedTech to Support Expansion into Italy
- New Research: Deterministic Decompilation of Hermes Bytecode Back to Readable JavaScript
- The J. Wes Project Celebrates 11 Years of Love, Music & Inspiration
- Lionheart Holdings and KEO Energy Sign Letter of Intent for Proposed Business Combination
On this news, bluebird's stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (2) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
- MoMojo Records announces new album from Jad Tariq
- Marcus Christ Announces Singles: "The Hammer Goes Click" and "You Hate Me, I Hate You"
- Fatal FOMO May be Your Last Roll of the Dice
- Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
- Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
If you purchased or otherwise acquired bluebird securities during the Class Period, you may move the Court no later than April 13, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The PennZone
- CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
- Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
- Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
- Achugogo: Tale of the Spring Chaser Wins Inaugural TCCF Prize at Mifa Pitches, the Industry Market of the Annecy International Animation Film Festival
- Everything Policy Launches Madison, an AI Tool That Makes Legislation Readable for Students and Citizens
- Is the Market Missing One of the Most Undervalued Cybersecurity Companies on the Stock Market? Cycurion, Inc. (N A S D A Q: CYCU):
- Billion-Dollar Scale Global Technology Powerhouse Being Built with Expanding Government Contracts: Circle8 Group (N A S D A Q: CIRC)
- Nevada Boxing Hall of Fame Gears Up for Star-Studded 14th Annual Induction Gala Weekend
- MedSocially Expands Access to Healthcare Networking Platform
- New Thriller 'Counterframe' Explores the Hidden Vulnerabilities of Modern Society
- Award-Winning Heritage at South Brunswick Continues to Thrive as One of New Jersey's Premier New Home Communities
- Four Seasons Cleaners Debuts Santa Barbara County's First 24/7 Dry Cleaning Kiosk New self-service
- WhereTu Launches to Help Americans Build Successful Lives Abroad
- Alcom Printing Achieves SGP Recertification
- John Marc Rittle Receives Pennsylvania's Most Influential Leaders Award
- Appliance EMT Expands Built-In and Walk-In Refrigerator Service in Metro Atlanta
- LawProactive Launches SB 37-Compliant Attorney Marketing Software With Exclusive City Territories Across California
- Cogs and Marvel expands EMEA leadership team for next phase of growth
- Beat the Philly Heat: Mid-July AC Boost
- Dave Freer's "Storm-Dragon" Wins First-Ever Prometheus Special Award For Young Adult Fiction